Leap Therapeutics Inc (LPTX NASDAQ) stock market data APIs
$0.3168
-0.03(-9.5%)
as of July 8, 2025
Try our APIs with
free plan!
Leap Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Prev. Close
0.3168
Open
0.2876
High
0.3219
Low
0.2841
52 wk Range
0.2223-4.79
Market Cap
11 761 K
Shares Outstanding
41 440 K
Revenue
375 K
Beta
-0.223
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Leap Therapeutics Inc data using free add-ons & libraries
Get Leap Therapeutics Inc Fundamental Data
Leap Therapeutics Inc Fundamental data includes:
- Net Revenue: 375 K
- EBITDA: -71 338 752
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-02
- EPS/Forecast: -0.58
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Leap Therapeutics Inc News
New
Purple Biotech Appoints Shai Lankry as Chief Financial Officer
U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, i...
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
NEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflatio...
10 Most Promising Penny Stocks According to Analysts
In this article, we will take a look at the 10 most promising penny stocks according to analysts. To see more such companies, go directly to 5 Most Promising Penny Stocks According to Analysts. Innov...
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients
CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, ba...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
